Jensen R T, Jones S W, Lu Y A, Xu J C, Folkers K, Gardner J D
Biochim Biophys Acta. 1984 Jun 19;804(2):181-91. doi: 10.1016/0167-4889(84)90148-4.
In the present study we examined the abilities of three analogs of substance P, [D-Pro2-, D-Phe7-, D-Trp9]-substance P, [D-Pro2-, D- Trp7 ,9]-substance P and [D-Arg1-, D-Pro2-, D- Trp7 ,9-, Leu11 ]-substance P to alter substance P-induced changes in pancreatic acinar cell function and to occupy substance P receptors. At 30 microM, each analog of substance P lacked agonist activity and inhibited amylase secretion stimulated by substance P receptor agonists. The inhibition was reversible and specific for peptides that interact with substance P receptors (physalaemin, substance P, eledoisin, kassinin ). The analogs of substance P did not inhibit the actions of cholecystokinin, caerulein, gastrin, carbamylcholine, secretin, vasoactive intestinal peptide, PHI, ionophore A23187 or 8Br -cAMP. At high concentrations, [D-Arg1-, D-Pro2-, D- Trp7 ,9-, Leu11 ]-substance P, but not [D-Pro2-, D- Trp7 ,9]-substance P or [D-Pro2-, D-Phe7-, D-Trp9]-substance P, caused a small but significant inhibition of bombesin-stimulated amylase release. For each analog of substance P, the inhibition was competitive in nature in that there was a rightward shift of the dose-response curve for physalaemin-stimulated amylase secretion with no change in efficacy. From Schild plots of the ability of [D-Arg1-, D-Pro2-, D- Trp7 ,9-, Leu11 ]-substance P to inhibit either substance p- or physalaemin-stimulated amylase release, the slopes were not different from unity. For each analog of substance P, there was a close correlation between its ability to inhibit substance P- or physalaemin-stimulated amylase release and its ability to inhibit binding of 125I-labeled substance P or 125I-labeled physalaemin. [D-Arg1-, D-Pro2-, D- Trp7 ,9-, Leu11 ]-substance P was 2-fold more potent than [D-Pro2-, D- Trp7 ,9]-substance P which was 4-fold more potent than [D-Pro2-, D-Phe7-, D-Trp9]-substance P, (i.e., pA2 6.1, 5.9, and 5.2, respectively). For each analog, the dose-response curve for its ability to inhibit physalaemin-stimulated amylase release was superimpossible on the dose-response curve for its ability to inhibit binding of 125I-labeled physalaemin. These results indicate that each of these analogs of substance P is a specific competitive inhibitor of the action of the substance P on dispersed acini from guinea-pig pancreas, and that their abilities to inhibit substance P-induced changes in acinar cell function can be accounted for by their abilities to occupy the substance P receptor.
在本研究中,我们检测了P物质的三种类似物,即[D-脯氨酸2-,D-苯丙氨酸7-,D-色氨酸9-] -P物质、[D-脯氨酸2-,D-色氨酸7,9-] -P物质和[D-精氨酸1-,D-脯氨酸2-,D-色氨酸7,9-,亮氨酸11] -P物质,改变P物质诱导的胰腺腺泡细胞功能变化以及占据P物质受体的能力。在30微摩尔浓度时,每种P物质类似物均缺乏激动剂活性,并抑制P物质受体激动剂刺激的淀粉酶分泌。这种抑制是可逆的,且对与P物质受体相互作用的肽(蛙皮素、P物质、eledoisin、kassinin)具有特异性。P物质类似物不抑制胆囊收缩素、蛙皮缩胆囊素、胃泌素、氨甲酰胆碱、促胰液素、血管活性肠肽、PHI、离子载体A23187或8-溴-cAMP的作用。在高浓度时,[D-精氨酸1-,D-脯氨酸2-,D-色氨酸7,9-,亮氨酸11] -P物质,但不是[D-脯氨酸2-,D-色氨酸7,9-] -P物质或[D-脯氨酸2-,D-苯丙氨酸7-,D-色氨酸9-] -P物质,对蛙皮素刺激的淀粉酶释放产生轻微但显著的抑制作用。对于每种P物质类似物,这种抑制本质上是竞争性的,即蛙皮素刺激的淀粉酶分泌的剂量反应曲线向右移动,而效能不变。从[D-精氨酸1-,D-脯氨酸2-,D-色氨酸7,9-,亮氨酸11] -P物质抑制P物质或蛙皮素刺激的淀粉酶释放能力的Schild图来看,斜率与1无差异。对于每种P物质类似物,其抑制P物质或蛙皮素刺激的淀粉酶释放的能力与其抑制125I标记的P物质或125I标记的蛙皮素结合的能力之间存在密切相关性。[D-精氨酸1-,D-脯氨酸2-,D-色氨酸7,9-,亮氨酸11] -P物质的效力比[D-脯氨酸2-,D-色氨酸7,9-] -P物质高2倍,而[D-脯氨酸2-,D-色氨酸7,9-] -P物质比[D-脯氨酸2-,D-苯丙氨酸7-,D-色氨酸9-] -P物质高4倍(即pA2分别为6.1、5.9和5.2)。对于每种类似物,其抑制蛙皮素刺激的淀粉酶释放能力的剂量反应曲线与其抑制125I标记的蛙皮素结合能力的剂量反应曲线相互重叠。这些结果表明,这些P物质类似物中的每一种都是P物质对豚鼠胰腺分散腺泡作用的特异性竞争性抑制剂,并且它们抑制腺泡细胞功能中P物质诱导变化的能力可以通过它们占据P物质受体的能力来解释。